Cardiff Oncology, Inc.
For the period ended Sep 30, 2026. Filed Nov 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 12, 2026
CRDF$0.73-4.9%Stored close · as of Nov 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
Checking your notes…
| PreferredStockShares | PreferredStockAmount | CommonStockShares | CommonStockAmount | Additional Paid-InCapital | AccumulatedOtherComprehensiveGain (Loss) | AccumulatedDeficit | TotalStockholders’Equity | |
|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2025 | 61 | $— | 68,305 | $7 | $475,361 | $50 | $(430,030) | $45,388 |
| Stock-based compensation | — | — | — | — | 1,660 | — | — | 1,660 |
| Issuance of common stock upon exercise of stock options | — | — | 65 | — | 105 | — | — | 105 |
| Other comprehensive loss | — | — | — | — | — | (99) | — | (99) |
| Net loss | — | — | — | — | — | — | (12,345) | (12,345) |
| Balance, March 31, 2026 | 61 | — | 68,370 | 7 | 477,126 | (49) | (442,375) | 34,709 |
| Stock-based compensation | — | — | — | — | 920 | — | — | 920 |
| Issuance of common stock, net of expenses(1) | — | — | 132 | — | 148 | — | — | 148 |
| Other comprehensive loss | — | — | — | — | — | (13) | — | (13) |
| Net loss | — | — | — | — | — | — | (9,232) | (9,232) |
| Balance, June 30, 2026 | 61 | — | 68,502 | 7 | 478,194 | (62) | (451,607) | 26,532 |
| Stock-based compensation | — | — | — | — | 1,343 | — | — | 1,343 |
| Issuance of common stock and warrants, net of expenses(2) | — | — | 9,293 | 1 | 9,129 | — | — | 9,130 |
| Issuance of common stock upon exercise of stock options | — | — | — | — | — | — | — | — |
| Other comprehensive loss | — | — | — | — | — | (50) | — | (50) |
| Net loss | — | — | — | — | — | — | (8,857) | (8,857) |
| Balance, September 30, 2026 | 61 | $— | 77,795 | $8 | $488,666 | $(112) | $(460,464) | $28,098 |
(1)Net of expenses of $64
(2) Net of expenses of $920
CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY
| PreferredStockShares | PreferredStockAmount | CommonStockShares | CommonStockAmount | Additional Paid-InCapital | AccumulatedOtherComprehensiveGain | AccumulatedDeficit | TotalStockholders’Equity | |
|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2024 | 61 | $— | 66,524 | $7 | $467,087 | $34 | $(384,179) | $82,949 |
| Stock-based compensation | — | — | — | — | 1,365 | — | — | 1,365 |
| Issuance of common stock upon exercise of stock options | — | — | 2 | — | 3 | — | — | 3 |
| Other comprehensive loss | — | — | — | — | — | (7) | — | (7) |
| Net loss | — | — | — | — | — | — | (13,434) | (13,434) |
| Balance, March 31, 2025 | 61 | — | 66,526 | 7 | 468,455 | 27 | (397,613) | 70,876 |
| Stock-based compensation | — | — | — | — | 1,683 | — | — | 1,683 |
| Other comprehensive loss | — | — | — | — | — | (10) | — | (10) |
| Net loss | — | — | — | — | — | — | (13,943) | (13,943) |
| Balance, June 30, 2025 | 61 | — | 66,526 | 7 | 470,138 | 17 | (411,556) | 58,606 |
| Stock-based compensation | — | — | — | — | 1,384 | — | — | 1,384 |
| Issuance of common stock upon cashless exercise of warrants | — | — | 553 | — | — | — | — | — |
| Issuance of common stock upon exercise of stock options | — | — | 16 | — | 25 | — | — | 25 |
| Other comprehensive gain | — | — | — | — | — | 33 | — | 33 |
| Net loss | — | — | — | — | — | — | (11,258) | (11,258) |
| Balance, September 30, 2025 | 61 | $— | 67,095 | $7 | $471,547 | $50 | $(422,814) | $48,790 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.